durvalumab and tremelimumab


( Last Updated : November 17, 2022)
Generic Name:
durvalumab and tremelimumab
Project Status:
Pending
Therapeutic Area:
unresectable hepatocellular carcinoma
Manufacturer:
AstraZeneca Canada Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
PC0308-000
Call for patient/clinician input closed:
Tumour Type:
Endocrine

Details


Manufacturer Requested Reimbursement Criteria1:
Tremelimumab for injection in combination with durvalumab is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Tremelimumab for injection in combination with durvalumab is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.